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Werner syndrome (WS, OMIM: 277700) is an 
autosomal recessive progeroid syndrome characterized 
by the appearance of multiple features of aging begin-
ning in early adulthood. Approximately 90% of 
individuals presenting with WS have mutations in the 
WRN gene, which encodes a 1432 amino acid protein 
with a central domain characteristic of members of the 
Rec Q family of helicases. The clinical phenotype of 
WS includes scleroderma-like skin changes, bilateral 
ocular cataracts, type 2 diabetes mellitus, osteoporosis, 
hypogonadism, and atherosclerosis. The most common 
causes of death are cancer and myocardial infarction 
and the average age at death is 54 years [1, 2].  
 
 
Little is known about the association of epigenetic 
alterations with WS. Several recent studies have 
proposed to measure the physiological age of tissue 
samples by combining the DNA methylation levels of 
multiple dinucleotide markers, known as Cytosine 
phosphate Guanines or CpGs [3-7]. In particular, the 
“Epigenetic Clock” was developed to measure the age 
of sorted human cell types (CD4+ T cells or neurons), 
all tissues, and organs including blood, brain, breast, 
kidney, liver, and lung [6]. The epigenetic clock is 
defined as a weighted average across 353 CpG sites. 
The resulting age estimate (in units of years) is referred 
to as "DNA methylation age" (DNAm age) or 
"epigenetic age". Recent studies support the idea that 
epigenetic age estimates are at least  passive  biomarkers  


























we  find  that  WS  is  associated  with  increased  extrinsic  epigenetic  age  acceleration  (p=0.0072)  and  intrinsic
epigenetic  age  acceleration  (p=0.04),  the  latter  of  which  is  independent  of  age‐related  changes  in  the
composition  of  peripheral  blood  cells. A multivariate model  analysis  reveals  that WS  is  associated with  an
increase  in DNA methylation age  (on average 6.4 years, p=0.011) even after adjusting  for  chronological age,
gender, and blood cell counts. Further, WS might be associated with a reduction in naïve CD8+ T cells (p=0.025)
according  to  imputed measures of blood cell counts. Overall,  this study shows  that WS  is associated with an
increased epigenetic age of blood cells which is independent of changes in blood cell composition. The extent to
which this alteration is a cause or effect of WS disease phenotypes remains unknown. 
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of biological age. For instance, the epigenetic age of 
blood has been found to be predictive of all-cause 
mortality [8-12], frailty [13], lung cancer [14], and 
cognitive and physical functioning [15]. Further, the 
utility of the epigenetic clock method using various 
tissues and organs has been demonstrated in studies of 
Alzheimer's disease [16], centenarian status [10, 17], 
Down syndrome [18], HIV infection [19], Huntington's 
disease [20], obesity [21], lifetime stress [22], menopause 
[23], osteoarthritis [24], and Parkinson's disease [25]. 
Despite many diverse applications of the epigenetic 
clock, we are not aware of any studies that have analyzed 
epigenetic aging rates in WS. 
 
Here we show for the first time that measures of 
epigenetic age acceleration are indeed associated with 








































ciation studies (EWAS) that interrogate individual 
CpGs, the current study posits a single hypothesis: WS 
is associated with epigenetic age acceleration in blood 
cells. In a secondary analysis, we also relate WS status 
to abundance measures of blood cell types that were 




Subjects and tissue 
 
We analyzed DNA methylation levels by the Illumina 
Infinium MethylationEPIC BeadChip in whole blood of 
18 patients with confirmed mutations in the WRN gene 
(16 male, 2 female) and 18 controls, which were 
matched for age and for gender (with one exception: 15 











































acceleration.  (B) presents  results  for  the  "universal" measure of epigenetic age acceleration, which  is defined as  residual  to a
regression  line  through  the  control  samples,  i.e.  the  vertical  distance  of  a  point  from  the  line.  By  definition,  the mean  age
acceleration  in  controls  is  zero.  (C)  The  bar  plots  relate measures  of  intrinsic  epigenetic  age  acceleration  to WS  status.  This
measure is independent of blood cell counts. (D) shows findings for the measure of extrinsic epigenetic age acceleration, which
does relate  to changes  in cell composition. Each bar plot depicts  the mean value  (y‐axis), 1 standard error, and  the group size
(underneath the bar). The p‐value results from the Kruskal Wallis test, which is a non‐parametric group comparison test. 




















































Accuracy of the epigenetic clock 
 
DNAm age (also referred to as epigenetic age) was 
calculated as described in [6]. Mathematical details and 




















































in the Additional files of [6]. An online age calculator 
can be found at our webpage (https://dnamage.genetics. 
ucla.edu). All of the described epigenetic measures of 
aging and age acceleration are implemented in our 
freely available software. 
Table 1. Sample characteristics of matched WS cases and controls. 
Sample ID Disease status Registry # gender age 
PWM18 WS CHAR1010 male 18 
CM18 control male 18 
PWM22 WS KERA1010 male 22 
CM22 control male 22 
PWF31 WS PA1010 female 31 
CF31 control female 31 
PWM32 WS BOERN1010 male 32 
CM32 control male 32 
PWF36 WS TIT1010 female 36 
CF36 control female 36 
PWM37-1 WS AFRI1010 male 37 
CM37-1 control male 37 
PWM37-2 WS TORON1010 male 37 
CM37-2 control male 37 
PWM37-3 WS VELO1010 male 37 
CM37-3 control male 37 
PWM38 WS ZE1010 male 38 
CM38 control male 38 
PWM39 WS MASS1010 male 39 
CM39 control male 39 
PWM40 WS MARY1010 male 40 
CM40 control male 40 
PWM43-1 WS HAWI1010 male 43 
CM43-1 control male 43 
PWM43-2 WS NY1010 male 43 
CM43-2 control male 43 
PWM45-1 WS BIA1010 male 45 
CM45-1 control male 45 
PWM45-2 WS USC1010 male 45 
CM45-2 control male 45 
PWM47 WS CHAP1010 male 47 
CM47 control male 47 
PWM49 WS CONST1010 male 49 
CM49 control male 49 
PWF59 WS TY1010 female 59 
CM59 control   male 59 
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As expected, DNAm age has a strong linear relationship 
with chronological age (r=0.83, Figure 1A). 
 
Werner syndrome is associated with intrinsic and 
extrinsic epigenetic age acceleration 
 
In this article, we consider three measures of 
epigenetic age acceleration (Methods). The first 
measure, which will be referred to as a universal 
measure of age acceleration (denoted AgeAccel) 
applies to virtually all tissues and cell types (with the 
exception of sperm). The other two measures (referred 
to as intrinsic and extrinsic age acceleration, 
respectively) only apply to peripheral blood cells. The 
universal measure AgeAccel is defined as the 
difference between DNAm age value and the value 
predicted by a linear regression model in controls. The 
measure of intrinsic epigenetic age acceleration 
(IEAA) measures "pure" epigenetic aging effects in 
blood cells that are not confounded by differences in 
blood cell counts. The measure of extrinsic epigenetic 
age acceleration (EEAA) aims to measure aging in 
immune related components and also relates to age- 
associated changes in blood cell composition such as 
the decrease of naïve CD8+ T cells and the increase in 
memory or exhausted CD8+ T cells [26-28]. EEAA is 
defined on the basis of a weighted average of the 
epigenetic age measure from [5] and three blood cell 
types that are known to change with age: naïve 
(CD45RA+CCR7+) cytotoxic T cells, exhausted 
(CD28-CD45RA-) cytotoxic T cells, and plasma B 
cells. By definition, EEAA has a positive correlation 
with the amount of exhausted CD8+ T cells and plasma 
blast cells and a negative correlation with the amount of 
naïve CD8+ T cells. Blood cell counts were estimated 
based on DNA methylation data as described in 
Methods. By construction, our three measures of 
epigenetic age acceleration are uncorrelated (r=0) with 


















WS is significantly associated with epigenetic age 
acceleration according to all three measures of 
epigenetic age acceleration (Figure 1B,C,D). The 
strongest association can be observed for EEAA 
(p=0.0072). 
 
To estimate the actual amount of age acceleration, we 
regressed DNAm age on disease status, age, gender, and 
blood cell count estimates. According to this multi-
variate regression model, the blood of WS cases is 6.4 
years older than that of age matched controls (Table 2).  
 
Conditional logistic regression analysis 
 
Our previous multivariate linear model analysis ignored 
the fact that cases and controls were grouped into 
matched pairs. To adjust for this matched pair design, 
we used a conditional logistic regression analysis that 
automatically adjusted for chronological age and 
gender. According to univariate conditional logistic 
regression models, WS status (dependent variable) is 
significantly associated with AgeAccel (p=0.047, 
regression coefficient=0.258, standard error=0.130), 
IEAA (p=0.045, coef=0.271, SE=0.135) and to a lesser 
extent with EEAA (p=0.071, coef=0.164, SE=0.0907).  
 
Suggestive evidence for a decreased abundance of 
naïve CD8+ T cells in Werner syndrome  
 
In a secondary analysis, we related disease status to 
blood cell count estimates based on DNA methylation 
data (Figure 2). Comparison of age adjusted blood cell 
counts between WS patients and controls revealed a 
significant decrease of naïve CD8+ T cells 
(CD8+CD45RA + CCR7+) in WS cases (p=0.025, 
Figure 2C). However, the p-value (p=0.025) is not 
significant after adjusting for multiple comparisons. 
Further, WS was not associated with naïve CD8+ T 



















Covariate Coef Std. Error T-statistic P-value 
Age 0.66293 0.103509 6.4046 6.2x10-7 
Werner Syndrome 4.250449 1.560597 2.7236 0.011 
Gender(female) -1.97987 2.141069 -0.9247 0.36 
CD4+T cell 35.42897 27.09406 1.3076 0.20 
Granulocyte 34.03732 19.64958 1.7322 0.094 
Natural Killer cell 17.97726 24.01823 0.7484 0.46 
Naïve CD8+ T cell -0.00363 0.021163 -0.1716 0.86 
DNA methylation age (outcome) is regressed on chronological age, disease status, gender, and blood 
cell counts. Note that WS is associated with an increased age of 4.250449/0.662930=6.4 years. 































sis  (p=0.16)  that  adjusted  for the matched pair 
design. None of the blood cell counts were related to 
WS status according to our conditional logistic 




Using a novel DNA methylation data set, we 
demonstrate accelerated epigenetic aging effects in WS. 
WS has a significant relationship with all three 
measures of epigenetic age acceleration. The observed 
accelerated epigenetic aging effects do not reflect 
confounding due to changes in blood cell composition 
because a) they can be observed for cell-intrinsic 
measures of age acceleration (IEAA) and b) they remain 
significant in multivariate models that adjust for blood 
cell counts.  
 
Since all of our WS cases had confirmed mutations in 
the WRN gene, the epigenetic aging effects must be a 
consequence of loss of function mutations in the WRN 
gene. In the following, we discuss several theories that 

































The helicase theory of accelerated epigenetic aging 
 
The WRN gene encodes a 1432 amino acid protein with 
a central domain characteristic of members of the Rec Q 
family of helicases. Since the WRN probably plays an 
important role in a DNA helicase it stands to reason that 
the observed accelerated epigenetic aging effect in WS 
results from a process in which DNA helicases play an 
important role. More generally it might result from a 
process that involves both DNA and RNA helicases. 
Helicases are enzymes that bind and may even remodel 
nucleic acid or nucleic acid protein complexes. There 
are both RNA helicases and DNA helicases (such as 
WRN). DNA helicases function in cellular processes 
where double-stranded DNA must be separated, 
including DNA replication, DNA repair, and trans-
cription. By contrast, RNA helicases are involved in 
shaping the form of RNA molecules, during all 
processes involving RNA, such as transcription, 
splicing, and translation. Interestingly, two recent 
papers suggest that RNA helicases affect epigenetic 
aging rates in the cerebellum: a genome-wide 
association study of epigenetic aging rates in the 
cerebellum implicated DHX57 (DEAH-Box Helicase 
57) which is an RNA helicase [29]. Further, an epigene- 
Figure 2. Age adjusted blood cell counts versus Werner syndrome status. WS status (x‐axis) versus the age adjusted estimate of
(A) plasma blasts, (B) exhausted CD8+ T cells (defined as CD8+CD28‐CD45RA‐), (C) naïve CD8+ T cell count, (D) naïve CD4+ T cell count, (E)
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tic clock analysis of tissues from centenarians found 
that "helicase activity" might explain the finding that 
the cerebellum ages more slowly than other brain 
regions [17]. Overall, these results suggest that both 
RNA and DNA helicases affect epigenetic aging rates. 
The helicase theory of epigenetic aging has the 
following shortcomings. First, the relationship 
between RNA helicase activity and epigenetic age 
acceleration could only be observed in the cerebellum 
(and not yet in peripheral blood cells). Second, DNA 
helicases (such as WRN) may have little in common 
with RNA helicases. Third, helicase genes are not a 
smoking gun for any particular molecular process 
because they are ubiquitous and essential proteins for 
many processes. 
 
The epigenomic instability theory of accelerated 
epigenetic aging 
 
The WRN protein has exonuclease and helicase 
activities and is involved in DNA repair, DNA 
replication, recombination, transcription, and telomere 
maintenance [30, 31]. Thus, the discovery that loss of 
function of WRN is the cause of WS supports a major 
role for genomic instability as a fundamental 
mechanism of aging [32]. A recent study provides 
evidence of an important role of WRN in the 
maintenance of chromatin stability of mesenchymal 
stem cells [40]. We hypothesized that the epigenetic 
clock might relate to the actions of an epigenomic 
maintenance system [6]. Under this hypothesis, our 
results suggest that loss of function of WRN affects the 
epigenomic maintenance system resulting in increased 
epigenetic age. The main problem with the epigenomic 
instability theory of accelerated aging is the paucity of 
mechanistic details. 
 
The telomere theory of accelerated epigenetic aging 
 
This theory posits that epigenetic age acceleration in 
WS could result from telomere shortening. It was 
suggested that genomic instability is caused by telomere 
loss during DNA replication and that loss of WRN 
helicase activity promotes telomere loss [33]. 
Fibroblasts from WS patients grow poorly in culture 
and display a reduced lifespan. However, ectopic 
expression of telomerase in WS fibroblast cell lines 
partially rescues them from accelerated replicative 
senescence and increases genomic integrity [34, 35]. 
The average telomere erosion rate in bulk-cultured WS 
cells was shown to vary from that of normal fibroblasts 
to four times that of normal. At the single cell level, WS 
fibroblasts display telomere dynamics not significantly 
different from those in control fibroblasts, suggesting 
that the accelerated replicative senescence observed in 
WS fibroblasts is not caused by accelerated telomere 
shortening [36]. In contrast, an in vivo study showed 
that TRF (Telomere Restriction Fragment) lengths in 
skin samples of WS patients in their thirties were 
comparable with that of healthy samples, but were 
shorter in older WS patients compared to controls. 
Regression analyses is showed that the TRF length in 
skin and muscle of individuals with WS was 
significantly shorter than those in controls [37]. A major 
problem with this telomere theory of epigenetic age 
acceleration is that intrinsic epigenetic age acceleration 
is not correlated with telomere length in peripheral 
blood cells or adipose tissue [13, 21, 38].  
 
The immunosenescence theory of accelerated 
epigenetic aging 
 
This theory posits that the observed accelerated 
epigenetic aging effects in blood result from changes in 
blood cell composition that mirror those observed in 
immunosenescence. It is well known that a profound 
age-associated alteration in the T cell compartment is 
the reduction of naïve CD8+ T cells, which are involved 
in protection against infectious diseases and play an 
important role in immune surveillance against 
malignancies [27]. The theory is supported a) by our 
suggestive finding regarding the reduction of naïve 
CD8+ T cells in WS. However, the immunosenescence 
theory has several severe shortcomings including the 
following. First, the observed decrease in naïve CD8+ T 
cells only led to a p-value of 0.025 that is not significant 
after adjusting for multiple comparisons. This 
suggestive result requires replication in a larger study 
preferably involving flow cytometric measures. Second, 
the theory is inconsistent with our observed lack of an 
association between exhausted CD8+T cells and WS. 
Third, the observed epigenetic age acceleration effects 
are independent of changes in blood cell composition 




We acknowledge the following limitations. First, our 
sample size was relatively small (18 cases and 18 
controls). Second, we focused only on peripheral blood 
cells. Future studies should evaluate whether 
accelerated epigenetic aging effects can also be found in 
other tissues. Third, there is an interesting quantitative 
difference between the degree of accelerated epigenetic 
aging deduced from these peripheral blood cell studies 
of WS patients (6.4 years) and the premature ages of 
death of these patients. The most recently available data 
from both Japan and the US indicate that the mean age 
of death for WS patients is 54 years; this contrasts 
typical longevities in Japan of ~ 80 years and in the US 
of ~74 years [39, 40]. This discrepancy might reflect the 
fact that the epigenetic age of blood is only an 
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incomplete measure of organismal age. We believe that 
organismal age will be better estimated by combining 





We demonstrate that WS is associated with increased 
epigenetic age acceleration in blood according to 
several highly robust epigenetic measures of age 
acceleration. This finding reflects cell-intrinsic 
epigenetic aging effects that are independent of changes 
in cell composition. Epigenetic age acceleration of 
blood is not specific to WS but can also be observed in 
other conditions such as Down syndrome [18] and to a 
lesser extent in Parkinson's disease [25]. The degree to 
which these observed epigenetic age acceleration effects 
are causes or effects of the many geriatric disorders seen 
in WS remains unknown. A recent study providing 
evidence of an important role of WRN in the 
maintenance of chromatin stability of mesenchymal 
stem cells, however, is consistent with an important 
causal role [41]. 
 




Whole blood DNA samples of WS patients were sent to 
us from the International Registry of Werner Syndrome 
(http://www.wernersyndrome.org/; Seattle, WA). 
Whole blood samples of controls were collected in the 
Institute of Human Genetics of the University of 
Wuerzburg. Sodium bisulfite conversion of genomic 
DNA was performed using the EZ DNA Methylation™ 
Kit (Zymo Research, Irvine, CA, USA) according to the 
provided manual. The Infinium MethylationEPIC 
BeadChip (Illumina, San Diego, CA, USA) was used 
according to the manufacturer's protocol to analyze 
genome-wide DNA methylation. Chips were scanned 
by iScan (Illumina). Genome Studio (Illumina) was 
used for background subtraction and normalization to 
internal controls. 
 
Measures of epigenetic age acceleration 
 
The name of our universal measure of age acceleration 
(AgeAccel) reflects that it applies to virtually all sources 
of human DNA (with the exception of sperm). Here we 
defined it as follows. First, we regressed DNAm age on 
chronological age in controls. Next, we used the 
resulting model to predict the DNAm age of each 
subject. Next, the universal measure was defined as the 
difference between the observed measure of DNAm age 
and the predicted value. Thus, a high positive value for 
AgeAccel indicates that the observed DNAm age is 
higher than that predicted based on controls. AgeAccel 
has a relatively weak correlation with blood cell counts 
[19] but it still relates to blood cell counts. 
 
To subtract out the effect of blood cell counts, we find it 
useful to define a measure of intrinsic epigenetic age 
acceleration (IEAA) which measures "pure" epigenetic 
aging effects that are not confounded by differences in 
blood cell counts. It is defined as the residual resulting 
from a multivariate regression model of DNAm age on 
chronological age and various blood immune cell 
counts (naïve CD8+ T cells, exhausted CD8+ T cells, 
plasma B cells, CD4 T cells, natural killer cells, 
monocytes, and granulocytes).  
 
The measure of extrinsic epigenetic age acceleration 
(EEAA) aims to measure epigenetic aging in immune 
related components. EEAA is defined using the 
following three steps. First, we calculated the epigenetic 
age measure from Hannum et al based on 71 CpGs [5]. 
The resulting age estimate is correlated with certain 
blood cell types [9]. Second, we increased the 
contribution of blood cell types to the age estimate by 
forming a weighted average of the Hannum estimate 
with 3 cell types that are known to change with age: 
naïve (CD45RA+CCR7+) cytotoxic T cells, exhausted 
(CD28-CD45RA-) cytotoxic T cells, and plasma B cells 
using the approach of [42]. The resulting measure of 
blood age is referred to as BioAge4 in our epigenetic 
clock software. Third, we defined a measure of age 
acceleration (EEAA) as the residual resulting from a 
univariate model regressing BioAge4 on chronological 
age. By definition, our measure of EEAA has a positive 
correlation with the amount of exhausted CD8+ T cells 
and plasma blast cells and a negative correlation with 
the amount of naïve CD8+ T cells. EEAA is known as 
BioAge4HAStaticAdjAge in our software. 
 
Blood cell counts were estimated based on DNA 
methylation data as described in the section entitled 
"Estimating blood cell counts based on DNA 
methylation levels". By construction, EEAA tracks both 
age-related changes in blood cell composition and 
intrinsic epigenetic changes. By definition, none of our 
three measures of epigenetic age acceleration are 
correlated with the chronological age. IEAA differs 
across ethnic groups [43] but has a negligible 
association with behavioral/lifestyle factors [44].  
 
Estimating blood cell counts based on DNA 
methylation levels 
 
We estimate blood cell proportions using two different 
software tools. Houseman's estimation method [45], 
which is based on DNA methylation signatures from 
purified leukocyte samples, was used to estimate the 
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proportions of CD8+ T cells, CD4+ T, natural killer, B 
cells, and granulocytes. Granulocytes are also known as 
polymorphonuclear leukocytes. The advanced analysis 
option of the epigenetic clock software [6, 19] was used 
to estimate the percentage of exhausted CD8+ T cells 
(defined as CD28-CD45RA-) and the number (count) of 
naïve CD8+ T cells (defined as (CD45RA+CCR7+). 
Using another data set, we found that estimated blood 
cell counts correlate strongly with corresponding flow 
cytometric measurements r = 0.63 for CD8 + T cells, 
r = 0.77 for CD4+ T, r = 0.67 B cell, r = 0.68 naïve 
CD8+ T cell, r = 0.86 for naïve CD4+ T, and r = 0.49 for 
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